Karyopharm Therapeutics (KPTI) Upgraded to “Buy” at BidaskClub

BidaskClub upgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a hold rating to a buy rating in a report released on Friday morning.

A number of other equities research analysts have also weighed in on the stock. HC Wainwright restated a buy rating and issued a $23.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, November 15th. started coverage on shares of Karyopharm Therapeutics in a report on Wednesday, November 15th. They issued a buy rating and a $23.00 price objective on the stock. Royal Bank of Canada restated a buy rating and issued a $15.00 price objective on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. Robert W. Baird restated a buy rating on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. Finally, ValuEngine lowered shares of Karyopharm Therapeutics from a sell rating to a strong sell rating in a report on Wednesday, December 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $17.33.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) opened at $13.20 on Friday. Karyopharm Therapeutics has a fifty-two week low of $7.48 and a fifty-two week high of $14.63. The firm has a market cap of $619.48, a price-to-earnings ratio of -4.96 and a beta of 4.11.

In related news, SVP Christopher Brett Primiano sold 27,042 shares of Karyopharm Therapeutics stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $10.28, for a total transaction of $277,991.76. Following the sale, the senior vice president now directly owns 11,381 shares in the company, valued at approximately $116,996.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael Kauffman sold 10,000 shares of Karyopharm Therapeutics stock in a transaction on Monday, December 18th. The stock was sold at an average price of $9.16, for a total transaction of $91,600.00. Following the sale, the chief executive officer now owns 522,143 shares in the company, valued at $4,782,829.88. The disclosure for this sale can be found here. Insiders have sold a total of 78,542 shares of company stock worth $819,692 over the last quarter. 14.71% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in the stock. Citadel Advisors LLC raised its stake in Karyopharm Therapeutics by 51.1% during the 4th quarter. Citadel Advisors LLC now owns 54,308 shares of the company’s stock worth $521,000 after acquiring an additional 18,378 shares in the last quarter. Virtus Fund Advisers LLC purchased a new position in Karyopharm Therapeutics during the 4th quarter worth $355,000. Wells Fargo & Company MN grew its position in Karyopharm Therapeutics by 18.8% during the 4th quarter. Wells Fargo & Company MN now owns 30,974 shares of the company’s stock worth $298,000 after purchasing an additional 4,902 shares during the last quarter. Teacher Retirement System of Texas purchased a new position in Karyopharm Therapeutics during the 4th quarter worth $115,000. Finally, Schwab Charles Investment Management Inc. grew its position in Karyopharm Therapeutics by 7.1% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 150,289 shares of the company’s stock worth $1,443,000 after purchasing an additional 9,929 shares during the last quarter. Hedge funds and other institutional investors own 57.85% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://stocknewstimes.com/2018/02/13/karyopharm-therapeutics-kpti-upgraded-to-buy-at-bidaskclub.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply